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Abstract
Background: Increasing pneumococcal resistance to commonly used antibiotics and multidrug resistance is a
serious public health concern. Data on distribution of resistant Streptococcus pneumoniae (SPn) strains among
children in Lithuania are limited. We evaluated the circulation of SPn serotypes and antimicrobial susceptibility
among preschool children in Lithuania before the introduction of universal infant pneumococcal vaccination.
Methods: A prospective study was carried out from February 2012 to March 2013 in five cities of Lithuania. A total
of 900 children under six years of age who presented to primary care centre or a hospital emergency department
with acute respiratory tract infection were enrolled in the study. Nasopharyngeal swabs were obtained and cultured
for SPn. Positive samples (n = 367) were serotyped and tested for antimicrobial susceptibility. Associations of
pneumococcal non-susceptibility with study site, season, age, sex, attendance of day care centre and treatment
with antimicrobials (between one and six months prior the study) were evaluated.
Results: About a half (56.7 %) of SPn strains were susceptible to all the antibiotics tested. Pneumococcal
non-susceptibility to penicillin, erythromycin, clindamycin and trimethoprim–sulphamethoxazole was 15.8, 21.3, 16.9
and 27.3 %, respectively. None of the tested isolates was resistant to norfloxacin or vancomycin. We found a geographical
variation of pneumococcal resistance within the cities of the country. Age, sex, the attendance of day care centre and
treatment with antimicrobials prior the study was not significantly associated with a carriage of non-susceptible SPn
strains. Among non-susceptible SPn serotypes 67.9 %–82.4 % were present in currently available pneumococcal
conjugate vaccines.
Conclusions: The rates of nasopharyngeal SPn susceptibility to penicillin and macrolides are still high among preschool
children in Lithuania, however they are lower compared with previous studies. A strict policy with respect to antibiotic
prescription together with widespread use of vaccination could potentially reduce the carriage rate of antibiotic-resistant
pneumococci in our country.
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Background
Streptococcus pneumoniae (SPn) colonises the nasophar-
ynx and it may be asymptomatic or result in various types
of diseases including acute otitis media, sinusitis, pneumo-
nia, sepsis and meningitis, which are a considerable burden
[1, 2]. World Health Organization (WHO) estimated that
at the beginning of infants vaccination with pneumococcal
conjugated vaccines (PCV) 14.5 million cases of serious
illness and 7 % of all cause-child mortality [3] under five
years of age were due to pneumococcal infections. Despite
the effectiveness of PCV vaccination in different countries,
WHO reports that pneumococcal related deaths among
children under five years of age remains high [4]. Increasing
pneumococcal resistance to commonly used antibiotics
such as macrolides or cephalosporins and multidrug resist-
ance is another serious public health concern [5].
Antibiotic susceptibility of SPn has a large variation
among European countries. For example, non-susceptibility
to penicillin of non-invasive SPn isolates varies from
1.7 % in Norway [6] to 83 % in Romania [7] and non-
susceptibility to erythromycin varies from 1.2 % in the
Czech Republic [8] to 65.5 % in Italy [9]. Due to geograph-
ical diversity of the resistance of SPn strains dependent on
the local antimicrobial policy, epidemiological studies in
each geographical region are needed [10].
Data on distribution of resistant SPn strains among
children in Lithuania are limited. Only 37 and 59 SPn
strains, which caused invasive pneumococcal diseases in
children and adults, were tested for antimicrobial sus-
ceptibility in our country in 2012 and 2013, respectively
[11]. These findings do not necessarily reflect the actual
antimicrobial susceptibility of SPn in Lithuania and to
the moment there is no official data describing invasive
pneumococcal resistance among paediatric patients.
Three studies of SPn nasopharyngeal carriage and anti-
microbial susceptibility in healthy children have been per-
formed previously (in 1999, 2001 and 2006) [12, 13], in
which a total of 1625 children from the same 13 day-care
centres were enrolled. Non-susceptibility to penicillin in-
creased from 6.3 % in 1999 to 9.6 % in 2006. Higher
increase of non-susceptibility was observed to erythro-
mycin: 4.7 in 1999 and 9.6 % in 2006. These studies were
rather limited because all of them were performed during a
short period of time (in February and March) and the data
presented only one city of the country (Vilnius).
Our study performed in 2012–2013 evaluated the circu-
lation of SPn serotypes and antimicrobial susceptibility
among children with acute respiratory tract infection
(RTI) under six years of age in Lithuania before the intro-
duction of universal infants PCV vaccination in the coun-
try in October 2014 [14]. At the time of the study two
PCVs (10-valent (PCV-10) and 13-valent (PCV-13)) were
available only on private market. PCV vaccination cover-
age was unknown but probably it was low as vaccination
costs were relatively high and not reimbursed. Results of
this study might be the background for further investiga-
tions on the impact of PCV vaccination on the distribution
of resistant SPn serotypes in Lithuania, including the
widely discussed phenomenon of replacement in circulat-
ing resistant SPn serotypes due to vaccination [15]. SPn
colonisation rate, serotype distribution and the influence
on the clinical outcome were published separately [16, 17].
Methods
This prospective study was carried out from February
2012 to March 2013. Eight primary care centres (PCC)
in Lithuania’s five cities (Vilnius (n = 2), Kaunas (n = 2),
Klaipeda (n = 2), Panevezys (n = 1), Alytus (n = 1)) from
all main regions of the country and emergency department
(ED) of Children’s Hospital, Affiliate of Vilnius University
Hospital Santariskiu Klinikos in Vilnius were involved in
examining children for SPn nasopharyngeal carriage and
antimicrobial susceptibility.
Children under six years old, who visited a primary care
physician or a paediatrician because of either upper or
lower acute RTI, were enrolled into the study. The main
symptoms of acute RTI were acute onset, fever (37.2 °C or
higher), runny nose, sneezing, cough and sore throat. Chil-
dren were excluded if another cause of fever was identified
(e.g., confirmed urinary tract infection, etc.). Children were
not included if they had been vaccinated with any pneumo-
coccal vaccine (because of the vaccine’s effect on reducing
colonization with vaccine serotypes [18]) or had taken anti-
biotics within one month prior the enrolment (as this can
diminish the yield of nasopharyngeal culture samples [19]).
Nasopharyngeal swabs were taken at the time of enrol-
ment in the study using Culturette with Amies transport
medium (Deltalab, Spain) and transported to a certified
laboratory of Children’s Hospital, Affiliate of Vilnius
University Hospital Santariskiu Klinikos in Vilnius within
48 h from collection. Hare et al. compared several
methods for nasopharyngeal samples transport and found
Amies transport medium adequate for SPn detection [20].
However, according WHO skim milk-tryptone-glucose-
glycerol (STGG) remains the medium of choice for trans-
port and storage of nasopharyngeal swabs [21].
Classic cultural methods (cultivation in 5 % CO2, colony
morphology, Gram staining, catalase test, optochin sensitiv-
ity) were used to isolate SPn from the swabs [21, 22]. All
the isolates were sensitive to optochin. Bacterial antigen
rapid latex agglutination test (Wellcogen, Remel Europe
Limited, United Kingdom) was used for the confirmation.
Serotypes were determined by means of latex agglutination
reaction using the Pneumotest-Latex kit and selected Latex
Factor sera: 6b, 6c, 7b, 9 g, 18c, 18f, 19b, 19c and 23b
(Statens Serum Institut, Copenhagen, Denmark).
SPn susceptibility to penicillin was determined by disk-
diffusion method using 1 μg oxacillin disk (Bio-Rad,
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France). Isolates showing inhibition zones ≤19 mm were
confirmed by the penicillin Etest (bioMerieux, France).
Breakpoints of minimal inhibitory concentrations (MICs)
were interpreted according to the European Committee
on Antimicrobial Susceptibility Testing recommendations
(EUCAST, 2012) [23]. SPn strains were defined as penicil-
lin susceptible SPn (PSSP, MIC ≤0.06 mg/l), penicillin
intermediate SPn (PISP, MIC >0.06–2.0 mg/l) and penicil-
lin resistant SPn (PRSP, MIC >2 mg/l). PISP and PRSP
were grouped as penicillin non-susceptible SPn (PNSP).
Susceptibility to erythromycin, clindamycin, trimetho-
prim–sulphamethoxazole, norfloxacin and vancomycin
was determined by disk-diffusion method using Muel-
ler–Hinton agar, containing horse blood 5 % and 20 mg/
l ß-nicotinamide adenine dinucleotide (Bio-Rad, France).
Inoculated plates were incubated at 37 °C in 5 % CO2.
Results were interpreted according to EUCAST, 2012
[23]. Multidrug resistance (MDR) was defined as non-
susceptibility to penicillin and ≥2 other non–β-lactam
antimicrobial classes [24].
Statistical analysis
The data were analysed using SPSS (Statistical Package
for the Social Sciences) software 16. Multivariable Pois-
son regression with robust variance estimation was used
to assess the association of study site (PCCs of Kaunas,
Klaipeda, Panevezys vs Vilnius ED and PCC), season
(spring, autumn, winter vs summer), age (24–47 and
48–71 vs 0–23 months), sex (male vs female) and
attendance of day care centre (DCC; non-attending vs
attending) with SPn non-susceptibility. Univariable Pois-
son regression with robust parameter estimates was used
to analyse the associations of pneumococcal non-
susceptibility to separate antibiotics with sex, study site,
and treatment with antimicrobials (between one and six
months prior the study). Cross tabulation with chi-
squared test was used to test statistical significance for
differences between two groups. Statistical significance
was defined by p < 0.05.
Results
The data collected from the 900 study participants during
the one-year study period were analysed: 636 patients at
the PCCs and 264 at the hospital ED. The enrolled chil-
dren comprised 408 girls and 492 boys under six years of
age with acute RTI. The distribution of enrolled children
by sex and age was similar in all the cities, with the excep-
tion of Alytus, which may be due to a very small number
of study participants in this city (n = 18) [16].
A total of 367 SPn strains (one per patient) were isolated
from the 900 samples collected, giving a colonisation rate
of 40.8 %. A detailed analysis of SPn colonisation and
serotype distribution in relation to various factors were
published separately [16, 17].
All isolated SPn strains (n = 367) were tested for anti-
microbial susceptibility. About a half (56.7 %, n = 208) of
SPn strains were susceptible to all the antibiotics tested and
76 % (n= 279) were susceptible to penicillin and macrolides.
A single drug resistance was observed in 24.0 % (n = 88) of
SPn isolates with a predominance of non-susceptibility to
trimethoprim-sulphamethoxazole (19.3 %, n= 71). Dual
resistance was present in 5.2 (n = 19) and MDR - in 12.5 %
(n= 46) of SPn isolates.
The highest penicillin MIC was 2 mg/l. Hence, according
to the 2012 EUCAST breakpoints [23], none of the strains
fell into the resistant category, but 15.8 % (n = 58) were
PISP. Only 12.1 % (n = 7) of PISP were susceptible to other
antibiotics tested while other PISP were concomitantly
non-susceptible to erythromycin (82.8 %, n = 48), clindamy-
cin (77.6 %, n = 45) or trimethoprim-sulphamethoxazole
(34.5 %, n = 20). In addition, 8.6 (n = 5) of PISP showed dual
resistance, while 51.7 (n = 30) and 27.6 % (n = 16) were
resistant to 3 or 4 antibiotics tested, respectively.
SPn resistance to clindamycin was 16.9 % (n = 62). Higher
rates of resistance were present to erythromycin: 21.0
(n= 77) were resistant and 0.3 % (n= 1) was intermediately
susceptible. The highest non-susceptibility rates of pneumo-
cocci were found to trimethoprim-sulphamethoxazole,
whereas 21.0 (n= 77) were resistant and 6.3 % (n= 23) inter-
mediately susceptible. None of the tested isolates was resis-
tant to norfloxacin and vancomycin.
The rate of SPn antimicrobial non-susceptibility in re-
lation to various factors is summarized in Table 1. Anti-
biotic non-susceptibility of SPn was similar at ED
compared with PCCs, 44.6 (54/121) and 42.7 % (105/
246) respectively (PR (95 % CI) – 1.035 (0.854–1.255),
p = 0.724). A detailed analysis revealed a higher preva-
lence of PISP and MDR SPn at PCCs compared with ED
(19.1 % vs 9.1 %, PR (95 % CI) – 2.102 (1.131–3.904),
p = 0.019 for PISP and 15.4 % vs 6.6 %, PR (95 % CI) –
2.336 (1.125–4.852) p = 0.023 for MDR SPn, respect-
ively). Differences of SPn susceptibility to erythromycin,
clindamycin and trimethoprim-sulphamethoxazole
among those isolated from patients at PCCs and the
ED of the hospital were not statistically significant (p =
0.641, p = 0.188 and p = 0.613, respectively).
Antimicrobial non-susceptibility of SPn varied in differ-
ent studied sites of Lithuania: the highest rates were found
in Vilnius and the lowest – in Klaipeda (Table 1). Higher
rates of MDR and non-susceptibility to penicillin, erythro-
mycin and clindamycin were found in Panevezys while
non-susceptibility to trimethoprim-sulphamethoxazole
was more common in Vilnius (Fig. 1). Alytus was ex-
cluded from this comparison because of the small num-
ber of SPn isolates (n = 18). Sex and age were not
significantly associated with carriage of non-susceptible
SPn strains (Table 1) but there was a tendency of higher
non-susceptibility to erythromycin (25.5 % vs 17.8 %, PR
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(95 % CI) - 1.428 (0.962–2.120), p = 0.077) and clindamycin
(20.0 % vs 14.4 %, PR (95 % CI) - 1.393 (0.884–2.195),
p = 0.153) in girls compared with boys. SPn non-
susceptibility to different antibiotics was similar among age
groups (Table 2). The attendance of DCC had no significant
effect to the susceptibility of pneumococci (Table 1).
A significant decrease of non-susceptibility to all tested
antibiotics was observed in summer compared to spring
(Table 1), but the differences to separate antibiotics were
not statistically significant. The rate of susceptible SPn
strains did not differ significantly between children who
were treated with antimicrobials during the period between
one and six months prior the nasopharyngeal sample and
children who were not (52.0 % (51/98) vs 57.4 % (143/249),
PR (95 % CI) - 0.906 (0.729–1.127), p = 0.376).
The most common serotypes of non-susceptible SPn
strains were 19 F (20.8, 33/159), 14 (15.7, 25/159), 6B
(14.5, 23/159), 15 (13.8, 22/159) and 23 F (13.8 %, 22/159).
Serotype distribution of SPn strains non-susceptible to
different antibiotics are shown in Fig. 2. Among non-
susceptible serotypes 67.9 (108/159) were present in
PCV10 (serotypes 1, 4, 5, 6B, 7 F, 9 V, 14, 18C, 19 F and
23 F) and 82.4 % (131/159) in PCV13 (serotypes 1, 3, 4, 5,
6A, 6B, 7 F, 9 V, 14, 18C, 19A, 19 F and 23 F). Among
MDR serotypes 73.9 (34/46) were present in PCV10 and
84.8 % (39/46) in PCV13.
Discussion
Susceptibility of non-invasive S. pneumoniae
The data presented illustrate the resistance of non-
invasive SPn to antimicrobials among preschool children
before the introduction of universal infants PCV
vaccination.
The rate of PSSP was quite high (84.2 %) and there were
no PRSP strains found in the nasopharynx. Similar results
were observed among invasive SPn isolates from children
and adults in our country during the study years: 83.8 in
2012 and 76.3 % in 2013 [11]. However, our findings indi-
cates lower PSSP rates than those in healthy children aged
2–7 years in the previous nasopharyngeal carriage studies
Table 1 Streptococcus pneumoniae non-suscebtibility in relation to various factors
Characteristic Susceptible isolates (n = 208), n (%) Non-susceptible isolates (n = 159), n (%) Total (n = 367) PR (95 % CI) P value
Age (months)
0–23b 49 (53.3) 43 (46.7) 92
24–47 117 (58.8) 82 (41.2) 199 0.953 (0.858–1.059) 0.370
48–71 42 (55.3) 34 (44.7) 76 0.992 (0.874–1.125) 0.895
Sex
Male 114 (56.4) 88 (43.6) 202 1.006 (0.937–1.081) 0.864
Femaleb 94 (57.0) 71 (43.0) 165
Day care centre attendance
Attendingb 153 (56.7) 117 (43.3) 270
Non-attending 53 (56.4) 41 (43.6) 94 1.013 (0.912–1.126) 0.808
Season
Spring 72 (52.9) 64 (47.1) 136 1.181 (1.024–1.363) 0.022
Summerb 23 (71.9) 9 (28.1) 32
Autumn 78 (59.1) 54 (40.9) 132 1.097 (0.947–1.270) 0.219
Winter 35 (52.2) 32 (47.8) 67 1.154 (0.990–1.344) 0.067
Cities of Lithuania
Vilnius PCC 45 (52.3) 41 (47.7) 86
ED 67 (55.4) 54 (44.6) 121
Totalb 112 (54.1) 95 (45.9) 207
Kaunas PCC 31 (59.6) 21 (40.4) 52 0.939 (0.843–1.046) 0.253
Klaipeda PCC 17 (70.8) 7 (29.2) 24 0.870 (0.733–1.033) 0.112
Panevezys PCC 47 (57.3) 35 (42.7) 82 0.985 (0.891–1.090) 0.774
Alytusa PCC 1 (50.0) 1 (50.0) 2
PCC primary care centre, ED the emergency department of Children’s Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos, Vilnius. PR (95 % CI) -
prevalence ratio and 95 % confidence interval of Streptococcus pneumoniae non-susceptibility to one or more antibiotics tested (penicillin, erythromycin,
clindamycin, trimethoprim–sulphamethoxazole, norfloxacin and vancomycin), using Multivariable Poisson regression
aNote that Alytus was excluded from this comparison because of the small number of S. pneumoniae isolates (n = 2)
bReference group for each comparison
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in Lithuania: 93.8 in 1999, 90.0 in 2001 and 90.4 % in
2006 [13].
A wide geographical variation exists in the prevalence
of PNSP nasopharyngeal carriage in Europe. The rates
of PNSP seen in our study (15.8 %) was higher to those
observed in healthy children in Norway (1.7) [6], the
Netherlands (2.7) [25], the Czech Republic (3) [8] and
Estonia (6 %) [26] before the widespread use of PCV
vaccination. Contrarily, results of pre-vaccination stud-
ies conducted in Greece [27], Poland [28] and Romania
[7] have shown higher rates of PNSP in healthy children:
34.7, 39.2 and 83 %, respectively. A decrease of resistance
to penicillin was reported due to the PCV vaccination
[29, 30].
According to our results, SPn susceptibility to erythro-
mycin and clindamycin was also high (78,7 and 83.1 %,
respectively). However, previously reported rates of naso-
pharyngeal SPn susceptibility to erythromycin and clinda-
mycin were even higher among healthy preschool children
in Vilnius (90.4 and 98 % in 2006, respectively) [13]. A
significant decrease (from 100 % to 82,1 %) of resistance to
macrolides of invasive SPn isolates was also observed
Fig. 1 Distribution of non-susceptible Streptococcus pneumoniae nasopharyngeal strains in the study sites of Lithuania. TMP-SMX - trimethoprim–
sulphamethoxazole; MDR - multidrug resistance. Study sites were primary care centres of Vilnius, Kaunas, Klaipeda, Panevezys and Alytus and the
emergency department of Children’s Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos in Vilnius. Note that Alytus was excluded from this
comparison because of the small number of S. pneumoniae isolates (n = 2). Using univariable Poisson regression analysis, significant differences were found
in these comparisons: non-susceptibility to penicillin was higher in Panevezys vs Vilnius (PR: 2.885, p = 0.000), non-susceptibility to erythromycin was higher in
Panevezys vs Vilnius (PR: 1.794, p = 0.007) and Kaunas (PR: 2.140, p = 0.035), resistance to clindamycin was higher in Panevezys vs Vilnius (PR: 2.621, p = 0.000)
and Kaunas (PR: 3.424, p = 0.007), non-susceptibility to TMP-SMX was higher in Vilnius vs Panevezys (PR: 1.659, p = 0.039) and MDR was higher in Panevezys
vs Vilnius (PR: 3.118, p = 0.000) and Kaunas (PR: 2.663, p = 0.035)
Table 2 Distribution of Streptococcus pneumoniae antimicrobial non-susceptibility among age groups
Age groups in
months
Non-susceptibility (ns) or resistance (r) to antibiotics, n (%) MDR, n (%)
Penicillin (ns) Erythromycin (ns) Clindamycin (r) TMP-SMX (ns)
0–23a (n = 92) 18 (19.6) 21 (22.8) 19 (20.7) 25 (27.2) 14 (15.2)
24–47 (n = 199) 27 (13.6) 40 (20.1) 31 (15.6) 53 (26.6) 23 (11.6)
P value 0.186 0.593 0.283 0.923 0.382
48–71 (n = 76) 13 (17.1) 17 (22.4) 12 (15.8) 22 (28.9) 9 (11.8)
P value 0.683 0.944 0.422 0.799 0.529
Total 58 (15.8) 78 (21.3) 62 (16.9) 100 (27.3) 46 (12.5)
TMP-SMX trimethoprim–sulphamethoxazole, MDR multidrug resistance
aReference group for each comparison (chi-squared test)
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during the period 2006–2013 in Lithuania [31]. It may be
due to an increased use of macrolides in the clinical
practice.
Non-susceptibility of non-invasive SPn strains to
erythromycin and clindamycin varies from 1.2 [8] to
65.5 [9] and from 0.6 % [8] to 49 % [32] in different
European countries, respectively. Our results are simi-
lar to those observed among non-invasive SPn strains
in paediatric population in Poland (29.5 and 29.2 %,
respectively) [28] and Russia (16.7 and 19.3 %, respect-
ively) [33] before routine PCV vaccination in these
countries.
High levels of SPn resistance to trimethoprim-sulphame
thoxazole were observed previously among non-invasive
strains in healthy preschool children in Lithuania [13].
Trimethoprim-sulphamethoxazole is not widely used to
treat respiratory tract infections in children, therefore the
non-susceptibility to trimethoprim-sulphamethoxazole de-
creased from 60.0 % in 1999 to 46.0 % in 2006 [13] and it
was 27.3 % in the current study. Pneumococcal resistance
to trimethoprim-sulphamethoxazole was found to be high
up to 66–67 % in Estonia [26] and Romania [7] while the
rates were lower in Norway (4.6) [6], the Netherlands (12.9)
[25] and the Czech Republic (15.7 %) [8].
Our data suggest that multidrug resistance of non-
invasive SPn among children in Lithuania (12.5 %) is inter-
mediate as compared with other European countries in
the pre-PCV-vaccination era. Higher rates of MDR strains
were found in Greece (25) [27], Poland (39.5) [28] and
Romania (67 %) [7], while lower rates were observed in
Norway (4.5) [6], Estonia (4) [26] and the Netherlands
(1.9 %) [25]. A decrease of resistance to macrolides,
trimethoprim-sulphamethoxazole and MDR was reported
due to the PCV vaccination [6, 30]. Resistance of SPn
varies not only among the countries. We found a
geographical variation of SPn resistance within the cities
of the country; therefore the attention should be paid to
the use of penicillin and macrolides in Panevezys and to
the use of trimethoprim-sulphamethoxazole in Vilnius.
It is important to note that most studies have focused on
SPn carriage in healthy children while in our study children
with acute RTI were enrolled. Similarly, Mayanskiy N et al.
examined antibiotic susceptibility of non-invasive SPn in
children aged under six years with symptoms of an acute
RTI and with chronic lung disease in Moscow, Russia.
Non-susceptibility to penicillin, erythromycin and MDR
was found in 28, 26 and 22 % of pneumococcal strains, re-
spectively [34]. We found a bit lower rates of SPn resistance
and it may be due to the enrolment of previous healthy
children or the differences in antibiotic policy.
Serotype distribution of resistant S. pneumoniae strains
Serotype distribution of resistant SPn strains has been
changed during different study years in Lithuania. Serotypes
6B, 9 V and 23 F were prevalent among PNSP strains in
2006 [13], while serogroups/serotypes 14, 19 F, 6A, 6B and
15 were the most common in the current study. Serotypes
23 F and 6B dominated among SPn strains non-susceptible
to erythromycin in 2006 [13] and serogroup 14, serotypes
19 F and 6B were the most common according to our data.
It is important to note, however, that the study sites and
the type of children studied differed, which limit the
comparison.
Serogroups 6, 9, 14, 19 and 23 accounted for most drug-
resistant SPn before widespread use of PCV in the USA
and European countries [7, 27, 35–39]. Our findings are in
accordance with this data with an exception of serogroup 9,
which was uncommon in our study, while serogroup 15
was more prevalent. The introduction and widespread use
of PCVs have changed the situation in many countries. For
Fig. 2 The most common serotypes of non-susceptible Streptococcus pneumoniae nasopharyngeal strains. TMP-SMX - trimethoprim–sulphamethoxazole;
MDR - multidrug resistance
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example, non-invasive PNSP isolates were mostly repre-
sented by serotypes 14, 23 F, 19 F, 6B, 9 V, 6A and 19A in
France, in 2001/2002. By contrast, serotypes 19A, 19 F
and non-PCV serotypes, particularly serotypes 11A, 15A,
15B/C, 29 and 35B were dominating after widespread use
of PCV vaccination in 2013/2014 [35]. The previously
highly prevalent resistant serotypes seem to be successfully
suppressed, and the emergence of new – often less resis-
tant, but sometimes more virulent and invasive – serotypes
is observed [39].
The data suggest that vaccination could potentially
reduce the carriage rate of antibiotic-resistant pneumo-
cocci in Lithuania as a majority (67.9 %–82.4 %) of non-
susceptible SPn serotypes belonged to serotypes included
in PCVs. Our study was performed before the implemen-
tation of the universal programme of PCV vaccination in
Lithuania, therefore it provides a basis for future compari-
sons of resistant SPn carriage and serotype distribution
between the pre- and post-vaccination era in the country.
It would be also helpful in improving antimicrobial policy
in Lithuania.
Conclusions
The rates of nasopharyngeal SPn susceptibility to penicillin
and macrolides are high among preschool children in
Lithuania, however they are lower compared with previous
studies. A strict policy with respect to antibiotic prescrip-
tion together with widespread use of vaccination could
potentially reduce the carriage rate of antibiotic-resistant
pneumococci in our country.
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